Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Lilly discloses new serotonergic agents

Sep. 6, 1996

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

BTG licenses analgesic combination to Forest

Sep. 6, 1996

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

New introductions for Faulding's sustained-release morphine product

Sep. 6, 1996

Analgesic and antiinflammatory agents superior to capsaicin

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...